Menu

Bio-Rad Introduces Isotype-Specific Secondary Antibodies

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced the launch of its isotype-specific secondary antibodies. This new range of recombinant monoclonal antibodies, directed against the three main mouse isotypes: IgG1, IgG2a, and IgG2b, offer improved signal detection and specificity in imaging, ELISA, flow cytometry, and western blotting.

Apr 9, 2019
Bio-Rad

Secondary antibodies are key components of antibody detection systems. The selection of an optimum secondary antibody can improve positive signals in addition to reducing false positive or negative staining. Recombinant monoclonal isotype-specific secondary antibodies detect individual isotypes, without species or isotype cross-reactivity, enabling multiple unlabeled mouse monoclonal antibodies of differing isotypes to be used simultaneously. This obviates the need to source secondary antibodies from other species. The isotype-specific antibodies offer an alternative to cross-adsorbed secondary antibodies when absolute specificity is required, for instance, during multiplexing or to prevent nonspecific background staining.


Bio-Rad’s recombinant monoclonal antibodies are generated using the Human Combinatorial Antibody Library (HuCAL®) and CysDisplay®, a proprietary method of phage display with guided selection methods to obtain highly targeted reagents. The recombinant production method also ensures consistent and secure supply.


“Recombinant human monoclonal antibodies are selected against epitopes unique to the isotype and offer significant advantages over traditional secondary antibodies,” said Tracey Long, Bio-Rad Marketing Manager, Life Science Group. “Bio-Rad’s recombinant monoclonal isotype-specific antibodies are easy to use and can be substituted for any secondary in the protocol without the need for extra steps,” she added.


Bio-Rad is a trademark of Bio-Rad Laboratories, Inc. in certain jurisdictions. HuCAL and CysDisplay are trademarks of MorphoSys AG.


July/August 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

Rapid Adoption of Carterra’s LSA™ Instrument Drives European Expansion
Rapid Adoption of Carterra’s LSA™ Instrument Drives European Expansion
Carterra® Inc., the world leader in high-throughput antibody screening and characterization, announced today that they have opened a Customer Experience Center (CEC) and office in Munich, Germany.
Microfluidics with a pharma focus<
Microfluidics with a pharma focus<
Microfluidics has rapidly grown in popularity in recent years, and new applications for the technology continue to be reported.
An In-Depth Introduction to Hybridoma-Based Antibody Development
An In-Depth Introduction to Hybridoma-Based Antibody Development
This white paper from GenScript introduces the process of creating hybridomas and using them for monoclonal antibody production.